US-based biopharma, Actuate Therapeutics’s elraglusib reduced the risk of death by 37% in a Phase I/II metastatic pancreatic cancer trial. The randomised Phase I/II trial (NCT03678883 ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
CHICAGO and FORT WORTH, Texas - Actuate Therapeutics, Inc. (NASDAQ: ACTU), a biopharmaceutical company with a market capitalization of $161.72 million, announced today that the... ByInvesting.com ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback